[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633085":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":126,"collaborators":11,"id":128,"slug":129,"hasResults":130,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":11,"eligibilityCriteria":134,"healthyVolunteers":130,"sex":135,"minAge":136,"maxAge":11,"enrollmentInfo":137,"targetDuration":11,"studyType":140,"phases":141,"briefSummary":143,"conditions":144,"keywords":148,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"ADARx Pharmaceuticals, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A - ADX-038 Monotherapy","EXPERIMENTAL",null,[13],"Drug: ADX-038",{"label":15,"type":10,"description":11,"interventionNames":16},"Part B - ADX-038 Combination Therapy",[13,17],"Drug: Telitacicept",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","ADX-038","siRNA duplex oligonucleotide",[9,15],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Telitacicept","fusion protein",[15],[29],{"name":30,"affiliation":31,"role":32},"Aditya Patel","ADARx Pharmaceuticals","STUDY_DIRECTOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Stephanie Leyva","CONTACT","877-232-7974","info@adarx.com",[40,54,62,71,80,89,98,106,112,119],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":11},"ADARx Clinical Site","RECRUITING","Shenzhen","Guangdong","518100","China","CN",{"type":49,"coordinates":50},"Point",[51,52],114.0683,22.54554,{"lat":52,"lon":51},{"facility":41,"status":42,"city":55,"state":56,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":57,"geoPoint":61,"contacts":11},"Guiyang","Guizhou",{"type":49,"coordinates":58},[59,60],106.71667,26.58333,{"lat":60,"lon":59},{"facility":41,"status":63,"city":64,"state":65,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":66,"geoPoint":70,"contacts":11},"NOT_YET_RECRUITING","Zhengzhou","Henan",{"type":49,"coordinates":67},[68,69],113.64861,34.75778,{"lat":69,"lon":68},{"facility":41,"status":42,"city":72,"state":73,"zip":74,"country":46,"countryCode":47,"cosmosGeoPoint":75,"geoPoint":79,"contacts":11},"Baotou","Inner Mongolia","014000",{"type":49,"coordinates":76},[77,78],109.84389,40.6516,{"lat":78,"lon":77},{"facility":41,"status":42,"city":81,"state":82,"zip":83,"country":46,"countryCode":47,"cosmosGeoPoint":84,"geoPoint":88,"contacts":11},"Wuxi","Jiangsu","214000",{"type":49,"coordinates":85},[86,87],120.28857,31.56887,{"lat":87,"lon":86},{"facility":41,"status":42,"city":90,"state":91,"zip":92,"country":46,"countryCode":47,"cosmosGeoPoint":93,"geoPoint":97,"contacts":11},"Yantai","Shandong","264008",{"type":49,"coordinates":94},[95,96],121.44081,37.47649,{"lat":96,"lon":95},{"facility":41,"status":42,"city":99,"state":11,"zip":100,"country":46,"countryCode":47,"cosmosGeoPoint":101,"geoPoint":105,"contacts":11},"Beijing","100034",{"type":49,"coordinates":102},[103,104],116.39723,39.9075,{"lat":104,"lon":103},{"facility":41,"status":42,"city":91,"state":11,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":107,"geoPoint":111,"contacts":11},{"type":49,"coordinates":108},[109,110],120.48412,40.28464,{"lat":110,"lon":109},{"facility":41,"status":42,"city":113,"state":11,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":114,"geoPoint":118,"contacts":11},"Shanghai",{"type":49,"coordinates":115},[116,117],121.45806,31.22222,{"lat":117,"lon":116},{"facility":41,"status":63,"city":120,"state":11,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":121,"geoPoint":125,"contacts":11},"Shangxi",{"type":49,"coordinates":122},[123,124],119.93205,29.28489,{"lat":124,"lon":123},{"type":127,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100633085","phase-2-chinese-adults-with-kidney-disease-100633085",false,"NCT07522099","Chinese Adults With Kidney Disease","A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease","Inclusion Criteria:\n\n* Mean eGFR greater than or equal to 30 mL\u002Fmin\u002F1.73m2\n* Clinical evidence of active kidney disease\n* Treated with supportive care including an ACE inhibitor or ARB if applicable\n* Willing to receive required vaccinations\n* Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy\n\nExclusion Criteria:\n\n* Previous kidney transplant or major solid organ transplant\n* Required renal replacement therapy for more than 72 hours\n* Rapidly progressive glomerular nephritis or acute kidney injury\n* History of recurrent invasive infection\n* Current or previous use of C5 or CFB inhibitors (such as eculizumab, ravulizumab or iptacopan)\n* Active TB, HIV or other systemic infection\n* Abnormal liver function","ALL","18 Years",{"count":138,"type":139},30,"ESTIMATED","INTERVENTIONAL",[142],"PHASE2","This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).",[145,146,147],"Immunoglobulin A Nephropathy (IgAN)","Complement 3 Glomerulopathy (C3G)","IC-MPGN",[149,150,147,151,152],"IgAN","C3G","complement mediated kidney diseases","IgA Nephropathy","2026-06-23",{"date":155,"type":156},"2026-06-25","ACTUAL",{"date":158,"type":156},"2026-05-21",{"date":160,"type":139},"2029-01-21",{"name":5,"class":6},10]